# Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA

> **NCT06856135** · — · AVAILABLE · sponsor: **Takeda**

## Conditions studied

- Crohn's Disease
- Ulcerative Colitis

## Interventions

- **DRUG:** Vedolizumab IV

## Key facts

- **NCT ID:** NCT06856135
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06856135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06856135, "Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06856135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*